Cheryl Ho

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America
    Cheryl Ho
    Department of Medical Oncology, BC Cancer Agency, Vancouver Clinic, BC, Canada
    Lung Cancer 49:225-31. 2005
  2. pmc Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
    Cheryl Ho
    British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Invest New Drugs 31:1587-91. 2013
  3. doi request reprint EGFR-directed therapies to treat non-small-cell lung cancer
    Cheryl Ho
    British Columbia Cancer Agency, Medical Oncologist, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Expert Opin Investig Drugs 18:1133-45. 2009
  4. ncbi request reprint Early clinical trial experience with vaccine therapies in non-small-cell lung cancer
    Cheryl Ho
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Lung Cancer 9:S20-7. 2008
  5. ncbi request reprint Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer
    Cheryl Ho
    University of California, Davis Cancer Center, Sacramento, CA, USA
    Clin Lung Cancer 8:420-4. 2007
  6. ncbi request reprint Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
  7. ncbi request reprint Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
  8. doi request reprint Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
  9. pmc Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
    Trevor J Pugh
    Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada
    BMC Cancer 7:128. 2007
  10. ncbi request reprint Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma
    Cheryl Ho
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:220-2. 2006

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America
    Cheryl Ho
    Department of Medical Oncology, BC Cancer Agency, Vancouver Clinic, BC, Canada
    Lung Cancer 49:225-31. 2005
    ....
  2. pmc Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
    Cheryl Ho
    British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Invest New Drugs 31:1587-91. 2013
    ..Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion...
  3. doi request reprint EGFR-directed therapies to treat non-small-cell lung cancer
    Cheryl Ho
    British Columbia Cancer Agency, Medical Oncologist, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Expert Opin Investig Drugs 18:1133-45. 2009
    ..This review discusses clinical studies with several new therapies and the plans for drug development...
  4. ncbi request reprint Early clinical trial experience with vaccine therapies in non-small-cell lung cancer
    Cheryl Ho
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Lung Cancer 9:S20-7. 2008
    ..Herein, we review the development and evolution of early lung cancer vaccine trials...
  5. ncbi request reprint Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer
    Cheryl Ho
    University of California, Davis Cancer Center, Sacramento, CA, USA
    Clin Lung Cancer 8:420-4. 2007
    ..Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition...
  6. ncbi request reprint Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
    ..Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy...
  7. ncbi request reprint Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
    ..We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors...
  8. doi request reprint Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
    ..Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism...
  9. pmc Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
    Trevor J Pugh
    Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada
    BMC Cancer 7:128. 2007
    ..We set out to examine the relationship between response and the molecular status of two such kinases, EGFR and HER2, in 39 patients treated with gefitinib at the BC Cancer Agency...
  10. ncbi request reprint Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma
    Cheryl Ho
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:220-2. 2006
  11. ncbi request reprint Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib
    Cheryl Ho
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 23:8531-3. 2005
  12. ncbi request reprint Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  13. pmc Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study
    Cheryl Ho
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Invest New Drugs 29:680-7. 2011
    ..Rash was evaluated using two additional validated dermatology methods: global acne grading scale (GAGS) and acne lesion counting (ALC). Tumor specimens and blood samples were obtained for correlative analyses...
  14. doi request reprint Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review
    Cheryl Ho
    Medical Oncology, BC Cancer Agency, Vancouver, BC and Department of Statistics, University of British Columbia, Vancouver, BC
    J Thorac Oncol 9:1180-6. 2014
    ..We hypothesize that the introduction of less toxic chemotherapy has increased treatment of advanced non-small-cell lung cancer resulting in improved survival...
  15. ncbi request reprint Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options
    Cheryl Ho
    Division of Hematology and Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:S118-25. 2006
    ..Research efforts continue to focus on identifying molecular markers and corresponding clinical features that will allow physicians to individualize patients' therapy...
  16. doi request reprint Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort
    Krista Noonan
    Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6 Canada
    Lung Cancer 86:344-9. 2014
    ..We sought to characterize the clinical effectiveness of chemotherapy in the general population by evaluating referral patterns, predictors of chemotherapy receipt and outcomes...
  17. doi request reprint Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC)
    Amanda Jagdis
    Department of Medicine, University of British Columbia Departments of Medical Oncology Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada
    Am J Clin Oncol 37:63-9. 2014
    ..The purpose of this study was to analyze the dose delivery and toxicity of weekly cisplatin versus high-dose cisplatin given every 3 weeks in a tertiary oncology clinic...
  18. doi request reprint The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials
    Krista L Noonan
    Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
    J Thorac Oncol 10:1523-31. 2015
    ..These factors include second-line or third-line therapy, maintenance chemotherapy, performance status selection, stage migration, sex migration, improved treatment of brain metastases, and better palliative care. ..
  19. doi request reprint Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility
    King Mong Tong
    Department of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada Electronic address
    Lung Cancer 87:296-302. 2015
    ..We propose to examine the proportion of patients eligible for maintenance and factors associated with the delivery of subsequent lines of chemotherapy...
  20. doi request reprint A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease
    Caroline Mariano
    British Columbia Cancer Agency, Department of Medical Oncology, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6 Electronic address
    Lung Cancer 83:73-7. 2014
    ..We hypothesized that in a population-based setting fewer patients receive second-line platin based chemotherapy than those enrolled in a clinical trial...
  21. ncbi request reprint The development of a standardized software platform to support provincial population-based cancer outcomes units for multiple tumour sites: OaSIS - Outcomes and Surveillance Integration System
    Jonn Wu
    BC Cancer Agency, Vancouver, British Columbia
    Stud Health Technol Inform 183:98-103. 2013
    ..This will also facilitate initiatives to improve patient outcomes, decision support in achieving operational efficiencies and an environment that supports knowledge generation...
  22. doi request reprint Implementation of a Lung Cancer Nurse Navigator Enhances Patient Care and Delivery of Systemic Therapy at the British Columbia Cancer Agency, Vancouver
    Kelly Zibrik
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Oncol Pract 12:e344-9. 2016
    ..The purpose was to improve referral practices, timelines, and availability of molecular testing for patients with advanced non-small-cell lung cancer (NSCLC)...
  23. ncbi request reprint Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis
    Cheryl Ho
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, Canada V5Z 4E6
    Clin Colorectal Cancer 5:279-82. 2005
    ..Capecitabine was approved for funding in the province of British Columbia in the spring of 2002 as an oral chemotherapeutic option for metastatic CRC...